Notice Number: NOT-CA-12-012
Release Date: March 12, 2012
National Cancer Institute (NCI)
This Notice serves to inform all interested persons and potential applicants that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has joined RFA-AI-12-004 entitled “Leadership Group for a Clinical Research Network on Therapeutics for HIV/AIDS and HIV-associated Infections in Adults (UM1)”. Through this participation, the NCI expects to augment support for research on HIV/AIDS-related malignancies within the Leadership Group Therapeutic Network (LG), which will be primarily supported by the National Institute of Allergy and Infectious Disease (NIAID).
The NCI is committed to developing more effective treatments for HIV-infected persons who develop HIV/AIDS-associated malignancies, including those associated with co-infections with oncogenic viruses such as human papillomavirus (HPV), Kaposi's sarcoma associated herpesvirus (KSHV/HHV-8), and Epstein Barr virus (EBV). This effort, which is domestic and international in scope, is coordinated through the NCI Office of HIV and AIDS Malignancy (OHAM).
To foster studies involving the development and testing of therapies for HIV-infected patients who have HIV/AIDS-associated malignancies, the NCI intends to help support meritorious projects that are based on collaborations involving investigators connected with the LG and investigators connected with the AIDS Malignancy Clinical Trials Consortium (AMC, http://pub.emmes.com/study/amc/public/index.htm) (and/or with other NCI-supported clinical trial groups, if appropriate). The AMC is a NCI-supported clinical trials group that is committed to enhancing therapeutic options for patients with HIV/AIDS-associated malignancies. The work of the AMC is conducted through the efforts of investigators at eight domestic and four international Clinical Trials Core Sites and their affiliates, and at an Operations and Data Management Center. Through these collaborative efforts, NCI may also help support studies of viruses responsible for causing HIV/AIDS-associated malignancies and strategies to prevent and detect the development of malignancies in HIV-infected individuals.
Catalog of Federal Domestic Assistance Numbers
93.393, 93.394, 93.395, 93.396, and 93.399.
Components of Participating Organizations
The Components of Participating Organizations section of RFA-AI-12-004 have been revised to include the NCI:
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute on Drug Abuse (NIDA)
National Institute on Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Cancer Institute (NCI)
NIAID and partner components listed above (including NCI) intend to commit up to an estimated total of $36.03M, depending on funds availability to awards made based on RFA-AI-12-004.
All other aspects of this FOA remain unchanged.
Please direct all inquiries to:
Mostafa Nokta, M.D., Ph.D.
Director, AIDS Cancer Clinical Program
Office of HIV and AIDS Malignancy (OHAM)
National Cancer Institute
31 Center Drive, Room 3A33
Bethesda, MD 20892-2440
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)